| Schizophrenia
Cobenfy vs Lybalvi
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Cobenfy vs Lybalvi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLybalvi has a higher rate of injection site reactions vs Cobenfy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lybalvi but not Cobenfy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cobenfy
Lybalvi
At A Glance
Oral
Twice daily
Muscarinic agonist/antagonist combination
Oral
Once daily
Atypical antipsychotic + opioid antagonist
Indications
- Schizophrenia
- Schizophrenia
- Bipolar I disorder
Dosing
Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.
Schizophrenia Initiate at 5 or 10 mg/10 mg orally once daily; recommended dose 10, 15, or 20 mg/10 mg once daily; maximum 20 mg/10 mg once daily.
Bipolar I disorder - monotherapy (manic or mixed episodes) Initiate at 10 or 15 mg/10 mg orally once daily; recommended dose 10, 15, or 20 mg/10 mg once daily; maximum 20 mg/10 mg once daily.
Bipolar I disorder - adjunct to lithium or valproate Initiate at 10 mg/10 mg orally once daily; recommended dose 10, 15, or 20 mg/10 mg once daily; maximum 20 mg/10 mg once daily.
Contraindications
- Urinary retention
- Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
- Gastric retention
- History of hypersensitivity to COBENFY or trospium chloride
- Untreated narrow-angle glaucoma
- Current opioid use
- Acute opioid withdrawal
Adverse Reactions
Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease
Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema
Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)
Most common (>=5%) Weight increased, somnolence, dry mouth, headache
Serious Neuroleptic malignant syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), metabolic changes (hyperglycemia, dyslipidemia, weight gain), tardive dyskinesia, orthostatic hypotension and syncope, leukopenia, neutropenia, agranulocytosis, dysphagia, seizures
Postmarketing Anaphylactoid reaction, angioedema, cholestatic or mixed liver injury, hepatitis, jaundice, diabetic coma, diabetic ketoacidosis, DRESS, fecal incontinence, hyperlipidemia, neutropenia, pancreatitis, priapism, rash, rhabdomyolysis, SIADH, somnambulism, stuttering, venous thromboembolic events
Pharmacology
Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.
The efficacy of olanzapine in schizophrenia and bipolar I disorder may be mediated through combined dopamine and serotonin type 2 (5HT2) antagonism; samidorphan is an opioid antagonist whose mechanism could be mediated through mu-, kappa-, and delta-opioid receptor antagonism.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cobenfy
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (8/12) · Qty limit (11/12)
Lybalvi
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (6/12) · Qty limit (10/12)
UnitedHealthcare
Cobenfy
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (2/8)
Lybalvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Cobenfy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Lybalvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Cobenfy Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Schizophrenia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CobenfyView full Cobenfy profile
LybalviView full Lybalvi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.